Neisseria gonorrhoeae: Difference between revisions
From IDWiki
Neisseria gonorrhoeae
(→: semantic citation) |
mNo edit summary |
||
| (20 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Background== |
|||
* Causes '''gonorrhea''' |
|||
*Causes '''gonorrhea''' |
|||
== Epidemiology == |
|||
===Microbiology=== |
|||
* Resistance |
|||
** About 50% resistance to [[fluoroquinolones]] |
|||
** Rates of MDR gonorrhea is increasing in Canada, mostly driven by [[azithromycin]] resistance |
|||
** XDR gonorrhea is still rare in Canada{{#scite:CCDR2019|type=journal|title=Multidrug-resistant and extensively drug-resistant gonorrhea in Canada, 2012–2016|journal=CCDR|year=2019|volume=45|issue=2/3|pages=45–53|doi=10.14745/ccdr.v45i23a01}} |
|||
*[[Stain::Gram-negative]] [[Shape::diplococcus]] within the genus [[Genus::Neisseria]] |
|||
== Clinical Presentation == |
|||
*Resistance |
|||
**MDR gonorrhea: resistance to one of [[azithromycin]] or a [[cephalosporin]] |
|||
**XDR if resistance to both [[azithromycin]] and a [[cephalosporin]] |
|||
=== |
===Epidemiology=== |
||
*Resistance |
|||
* Often asymptomatic |
|||
**About 50% resistance to [[fluoroquinolones]] |
|||
* Can cause anorectal pain, discharge, and pruritis |
|||
**Rates of MDR gonorrhea is increasing in Canada, mostly driven by [[azithromycin]] resistance |
|||
* Anal intercourse not required, especially in women |
|||
**XDR gonorrhea is still rare in Canada [[CiteRef::martin2019mu]] |
|||
===Mechanisms of Resistance=== |
|||
=== Disseminated gonococcal infection === |
|||
*[[β-lactamases]], most commonly a TEM-1-type contained on a Pc<sup>R</sup> plasmid |
|||
* Classically presents with tenosynovitis (often of wrists) or frank arthritis, with pustular lesions |
|||
*Altered [[penicillin-binding protein]] PBP-2, encoded by ''penA'' |
|||
* Diagnosed with genital testing for gonorrhea, ± blood cultures or arthrocentesis |
|||
*Altered or downregulated porins, encoded by ''penB'' |
|||
*Increased efflux pump, encoded by ''mtr'' |
|||
==Clinical Manifestations== |
|||
== Diagnosis == |
|||
=== Genital Infections === |
|||
* Resistance |
|||
** MDR gonorrhea: resistance to one of azithromycin or a cephalosporin |
|||
** XDR if resistance to both azithromycin and a cephalosporin |
|||
* Causes [[cervicitis]] and [[urethritis]] |
|||
== References == |
|||
* In women, up to 70% are asymptomatic |
|||
** In symptomatic women, the incubation period is about [[Usual incubation period::10 days]], followed by vaginal pruritis or mucopurulent discharge |
|||
** May have intermenstrual bleeding or menorrhagia |
|||
* In men and women with [[urethritis]], it is usually asymptomatic |
|||
** Incubation period is usually about [[Usual incubation period::3 to 5 days]], followed by urethral discharge and dysuria |
|||
* [[Epididymitis]] in men is more commonly caused by [[Chlamydia trachomatis]] |
|||
=== Pelvic Inflammatory Disease === |
|||
<references/> |
|||
* See [[Pelvic inflammatory disease]], of which about 40% of cases are caused by ''Neisseria gonorrhoeae'' |
|||
* Pelvic and abdominal pain, vaginal bleeding, and [[dyspareunia]] |
|||
* May be febrile and acutely unwell |
|||
=== Fitz-Hugh-Curtis Syndrome === |
|||
* Aka perihepatitis, with inflammation of Glisson's capsule around the liver |
|||
* More often associated with [[Chlamydia trachomatis]] |
|||
=== Bartholinitis === |
|||
* Inflammation of Bartholin's glands, which are behind the labia |
|||
* Labial pain, swelling, tenderness, and discharge |
|||
=== Anorectal Gonorrhea === |
|||
*Often asymptomatic |
|||
*Can cause anorectal pain, discharge, and pruritis |
|||
*Anal intercourse not required, especially in women |
|||
=== Pharyngitis === |
|||
===Disseminated Gonococcal Infection=== |
|||
*Occurs in about 1% of patients with gonorrhea, and most strains do not cause urethritis |
|||
**Risk factors include female sex, menstruation, pregnancy, and [[terminal complement deficiency]] |
|||
*Classically presents with either septic arthritis, or with a triad of tenosynovitis (often of wrists) dermatitis (with pustular lesions), and arthritis |
|||
*Diagnosed with genital testing for gonorrhea, ± blood cultures or arthrocentesis |
|||
*Other (rare) sites of dissemination include [[endocarditis]], [[meningitis]], and [[osteomyelitis]] |
|||
=== Conjunctivitis === |
|||
* Occurs in infants born to untreated, infected mothers, and rarely from spread by fomites or flies |
|||
==Differential Diagnosis== |
|||
*Other causes of [[urethritis]] or [[septic arthritis]] or [[proctitis]] |
|||
==Management== |
|||
*Anogenital and pharyngeal infection in people ≥9 years of age |
|||
**First-line: [[ceftriaxone]] 250 mg IM once plus [[azithromycin]] 1 g PO once |
|||
**Second-line: [[gentamicin]] 240 mg IM once (in 2 doses) plus [[azithromycin]] 2 g PO once |
|||
**Second-line: [[ciprofloxacin]] 500 mg PO once plus [[azithromycin]] 2 g PO once |
|||
*Disseminated gonococcal infection |
|||
**Arthritis: [[ceftriaxone]] 2 g IV q24h for 7 days, plus [[azithromycin]] 1 g PO once |
|||
**Meningitis: [[ceftriaxone]] 2 g IV q24h for 10-14 days, plus [[azithromycin]] 1 g PO once |
|||
**Endocarditis: [[ceftriaxone]] 2 g IV q24h for 28 days, plus [[azithromycin]] 1 g PO once |
|||
**Ophthalmia: [[ceftriaxone]] 2 g IV once, plus [[azithromycin]] 1 g PO once |
|||
*Repeat screening at 6 months |
|||
===Test of Cure=== |
|||
*Done at 3 to 7 days if by culture or 14 to 21 days if NAAT |
|||
*Indications include: |
|||
**Pharyngeal infection |
|||
**Persistent signs or symptoms |
|||
**Treated without ceftriaxone |
|||
**Treated with fluoroquinolone, without susceptibility testing |
|||
**Epidemiologic link to a resistant case |
|||
**Documented microbiologic resistance |
|||
**Epidemiologic link to treatment failure |
|||
**Previous treatment failure |
|||
**Uncertain adherence to treatment |
|||
**Reexposure to untreated partener |
|||
**Pregnancy |
|||
**Disseminated gonococcal infection |
|||
**Pediatric patient |
|||
**[[Pelvic inflammatory disease]] with documented gonorrhea |
|||
**Therapeutic abortion (increased risk of developing PID) |
|||
==Further Reading== |
|||
*[https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sexually-transmitted-infections.html#toc Canadian Guidelines on Sexually Transmitted Infections] |
|||
{{DISPLAYTITLE:''Neisseria gonorrhoeae''}} |
{{DISPLAYTITLE:''Neisseria gonorrhoeae''}} |
||
Latest revision as of 14:34, 9 February 2022
Background
- Causes gonorrhea
Microbiology
- Gram-negative diplococcus within the genus Neisseria
- Resistance
- MDR gonorrhea: resistance to one of azithromycin or a cephalosporin
- XDR if resistance to both azithromycin and a cephalosporin
Epidemiology
- Resistance
- About 50% resistance to fluoroquinolones
- Rates of MDR gonorrhea is increasing in Canada, mostly driven by azithromycin resistance
- XDR gonorrhea is still rare in Canada 1
Mechanisms of Resistance
- β-lactamases, most commonly a TEM-1-type contained on a PcR plasmid
- Altered penicillin-binding protein PBP-2, encoded by penA
- Altered or downregulated porins, encoded by penB
- Increased efflux pump, encoded by mtr
Clinical Manifestations
Genital Infections
- Causes cervicitis and urethritis
- In women, up to 70% are asymptomatic
- In symptomatic women, the incubation period is about 10 days, followed by vaginal pruritis or mucopurulent discharge
- May have intermenstrual bleeding or menorrhagia
- In men and women with urethritis, it is usually asymptomatic
- Incubation period is usually about 3 to 5 days, followed by urethral discharge and dysuria
- Epididymitis in men is more commonly caused by Chlamydia trachomatis
Pelvic Inflammatory Disease
- See Pelvic inflammatory disease, of which about 40% of cases are caused by Neisseria gonorrhoeae
- Pelvic and abdominal pain, vaginal bleeding, and dyspareunia
- May be febrile and acutely unwell
Fitz-Hugh-Curtis Syndrome
- Aka perihepatitis, with inflammation of Glisson's capsule around the liver
- More often associated with Chlamydia trachomatis
Bartholinitis
- Inflammation of Bartholin's glands, which are behind the labia
- Labial pain, swelling, tenderness, and discharge
Anorectal Gonorrhea
- Often asymptomatic
- Can cause anorectal pain, discharge, and pruritis
- Anal intercourse not required, especially in women
Pharyngitis
Disseminated Gonococcal Infection
- Occurs in about 1% of patients with gonorrhea, and most strains do not cause urethritis
- Risk factors include female sex, menstruation, pregnancy, and terminal complement deficiency
- Classically presents with either septic arthritis, or with a triad of tenosynovitis (often of wrists) dermatitis (with pustular lesions), and arthritis
- Diagnosed with genital testing for gonorrhea, ± blood cultures or arthrocentesis
- Other (rare) sites of dissemination include endocarditis, meningitis, and osteomyelitis
Conjunctivitis
- Occurs in infants born to untreated, infected mothers, and rarely from spread by fomites or flies
Differential Diagnosis
- Other causes of urethritis or septic arthritis or proctitis
Management
- Anogenital and pharyngeal infection in people ≥9 years of age
- First-line: ceftriaxone 250 mg IM once plus azithromycin 1 g PO once
- Second-line: gentamicin 240 mg IM once (in 2 doses) plus azithromycin 2 g PO once
- Second-line: ciprofloxacin 500 mg PO once plus azithromycin 2 g PO once
- Disseminated gonococcal infection
- Arthritis: ceftriaxone 2 g IV q24h for 7 days, plus azithromycin 1 g PO once
- Meningitis: ceftriaxone 2 g IV q24h for 10-14 days, plus azithromycin 1 g PO once
- Endocarditis: ceftriaxone 2 g IV q24h for 28 days, plus azithromycin 1 g PO once
- Ophthalmia: ceftriaxone 2 g IV once, plus azithromycin 1 g PO once
- Repeat screening at 6 months
Test of Cure
- Done at 3 to 7 days if by culture or 14 to 21 days if NAAT
- Indications include:
- Pharyngeal infection
- Persistent signs or symptoms
- Treated without ceftriaxone
- Treated with fluoroquinolone, without susceptibility testing
- Epidemiologic link to a resistant case
- Documented microbiologic resistance
- Epidemiologic link to treatment failure
- Previous treatment failure
- Uncertain adherence to treatment
- Reexposure to untreated partener
- Pregnancy
- Disseminated gonococcal infection
- Pediatric patient
- Pelvic inflammatory disease with documented gonorrhea
- Therapeutic abortion (increased risk of developing PID)
Further Reading
References
- ^ I Martin, P Sawatzky, V Allen, B Lefebvre, LMN Hoang, P Naidu, J Minion, P Van Caeseele, D Haldane, RR Gad, G Zahariadis, A Corriveau, G German, K Tomas, MR Mulvey. Multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae in Canada, 2012–2016. Canada Communicable Disease Report. 2019;45(2/3):45-53. doi:10.14745/ccdr.v45i23a01.
